期刊文献+

养心康对慢性心功能不全兔心室重构的影响 被引量:10

Effects of Yangxinkang on Ventricular Remodeling of Rabbit Model with Chronic Heart Failure
原文传递
导出
摘要 目的观察养心康对慢性心功能不全模型兔心室重构的影响。方法将25只新西兰兔造模成功后随机分为5组,即模型组,卡托普利组(1.2 mg.kg-1),养心康高、中、低剂量组(1.53,0.51,0.17 g.kg-)1,并设立空白对照组,每组5只。应用结扎兔冠状动脉的方法建立兔慢性心力衰竭模型,灌胃给药,每日一次,连续4周。观察兔心功能、心脏指数、室壁厚度和心肌细胞凋亡的情况。结果各给药组的心功能、心脏指数、室壁厚度和心肌细胞凋亡指数均有明显的改善,与模型组比较,有显著性差异(P<0.05或P<0.01)。结论养心康可以防治心衰模型兔的心室重构。 Objective To observe the effects of Yangxinkang on ventricular remodeling of the rabbit model with chronic heart failure.Methods The rabbit model of chronic heart failure was establised by ligation of left anterior descending coronary artery.Twenty-five New Zealand modeled rabbits were divided into model group,Captopril group(1.2 mg·kg-1),and low-dose,middle-dose and high-dose Yangxinkang groups(in the dosage of 1.53,0.51,0.17 g·kg-1,respectively).Five heathy rabbits served as the blank control group.The medication was carried out by intragastric administration once a day and for a total of 4 weeks.The effects of Yangxinkang on cardiac function,cardiac index,left ventricular wall thickness and myocardial cell apoptosis of the rabbit model were investigated.Results The cardiac function,cardiac index,left ventricular wall thickness and myocardial cell apoptosis of the administration groups were significantly improved,and the differences were statistically significant compared with model group(P 0.05 or P 0.01).Conclusion Yangxinkang can prevent ventricular remodeling of the rabbit model with chronic heart failure.
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2012年第1期58-60,共3页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 广州市科技局资助项目(2008A1-E4101)
关键词 养心康 慢性心功能不全 心脏指数 心室重构 Yangxinkang Chronic heart failure Cardiac index Ventricular remodeling Rabbits
  • 相关文献

参考文献7

二级参考文献16

  • 1刘建国,陶桂华,王风飞.充血性心力衰竭治疗前后超氧化物歧化酶和脂质过氧化物的变化(摘要)[J].中国循环杂志,1996,11(2):95-96. 被引量:5
  • 2徐叔云 卞如濂.药理实验方法学(第2版)[M].北京:人民卫生出版社,1994.366.
  • 3陈国伟 郑宗锷.现代心脏内科学[M].长沙:湖南科技出版社,1995.558.
  • 4杜晓军.实验性心力衰竭的动物模型[J].重庆医科大学学报,1998,13(1):74-74.
  • 5Kalon KL,Joan LP, William BK. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol, 1993,22 (Suppl A):6A-13A.
  • 6Hung YT, Cheug NT, Ip S. Epidemiology of heart failure in Hong Kong,1997. Hong Kong Med J, 2000,6:159-162.
  • 7Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001, 344:1651-1658.
  • 8Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J, 2001, 22: 1527-1561.
  • 9Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2001, 104:2996-3007.
  • 10中药新药研究指导原则.第二辑,中华人民共和国卫生部发布,1993:57-63.

共引文献407

同被引文献109

引证文献10

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部